Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax +/- Azacitidine in R/R MDS
NCT02966782Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of venetoclax in myelodysplastic syndrome (MDS) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Measurable Concentration (AUCt) for Azacitidine up to 32 days, Apparent Oral Clearance (CL/F) for Azacitidine up to 32 days and 10 more. Started Mar 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02966782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966782.